By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Mizuho Securities USA has initiated coverage of the diagnostics industry with an initial focus on the molecular diagnostics market.

The research is led by Peter Lawson, formerly an analyst with Thomas Weisel Partners.

This week, Lawson initiated coverage of several firms in the molecular diagnostics space including Beckman Coulter, Becton Dickinson, Cepheid, Gen-Probe, PerkinElmer, and Qiagen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.